MX2020012366A - Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor. - Google Patents

Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.

Info

Publication number
MX2020012366A
MX2020012366A MX2020012366A MX2020012366A MX2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A MX 2020012366 A MX2020012366 A MX 2020012366A
Authority
MX
Mexico
Prior art keywords
treatment
modified sugar
sugar groups
heat shock
shock protein
Prior art date
Application number
MX2020012366A
Other languages
English (en)
Inventor
Christopher F Bender
Gary Bolton
Chitase Lee
Melean Visnick
Xin Jiang
Bradley CAPRATHE
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2020012366A publication Critical patent/MX2020012366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a compuestos a base de biaril amidas y cumarinas con grupos de azúcar modificados que tienen las fórmulas: (ver Fórmulas) en donde las variables son como se definen en la presente; también se proporcionan composiciones farmacéuticas de los compuestos; estos derivados a base de biaril amida y cumarina con grupos de azúcar modificados son útiles para el tratamiento y prevención de enfermedades y trastornos, que incluyen trastornos neurológicos, tales como enfermedades neurodegenerativas y trastornos que dañan el nervio, por ejemplo, neuropatía periférica diabética.
MX2020012366A 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor. MX2020012366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
PCT/US2019/032292 WO2019222269A1 (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Publications (1)

Publication Number Publication Date
MX2020012366A true MX2020012366A (es) 2021-02-09

Family

ID=67002352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012366A MX2020012366A (es) 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.

Country Status (17)

Country Link
US (1) US11827664B2 (es)
EP (1) EP3794009A1 (es)
JP (1) JP2021524439A (es)
KR (1) KR20210021457A (es)
CN (1) CN112513058A (es)
AU (1) AU2019271126A1 (es)
BR (1) BR112020023277A2 (es)
CA (1) CA3100333A1 (es)
CL (1) CL2020002957A1 (es)
CO (1) CO2020015380A2 (es)
EA (1) EA202092727A1 (es)
IL (2) IL309891A (es)
MX (1) MX2020012366A (es)
PE (1) PE20211917A1 (es)
PH (1) PH12020551941A1 (es)
SG (1) SG11202011311YA (es)
WO (1) WO2019222269A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3099152C (en) 2018-05-14 2023-10-24 Gilead Sciences, Inc. Mcl-1 inhibitors
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
WO2021108254A1 (en) 2019-11-26 2021-06-03 Gilead Sciences, Inc. Processes and intermediates for preparing mcl1 inhibitors
US20230138729A1 (en) * 2021-09-13 2023-05-04 Rubedo Life Sciences, Inc. Coumarin Derivatives of Sugar Analogs and Uses Thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501465A (ja) 1990-09-07 1994-02-17 シェリング・コーポレーション 抗ウイルス化合物
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
EP1344780A4 (en) 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
CA2585091C (en) 2004-11-03 2016-07-19 University Of Kansas Novobiocin analogues as anticancer agents
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
EP2131656A4 (en) 2006-11-15 2011-12-07 Forest Lab Holdings Ltd phthalazine
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
NZ579635A (en) 2007-03-20 2011-07-29 Curis Inc Fused amino pyridine as hsp90 inhibitors
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2010014617A1 (en) 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
WO2012008435A1 (ja) 2010-07-13 2012-01-19 大日本住友製薬株式会社 ビアリールアミド誘導体またはその薬理学的に許容される塩
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
PT2812341T (pt) 2012-02-09 2019-11-22 Univ Kansas Inibidores c-terminal de hsp90
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
AU2014346483B2 (en) 2013-11-07 2019-01-17 The University Of Kansas Biphenylamide derivative Hsp90 inhibitors
WO2015070238A2 (en) 2013-11-11 2015-05-14 The University Of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
JP6793640B2 (ja) 2014-06-24 2020-12-02 ザ ユニバーシティ オブ カンザス Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド

Also Published As

Publication number Publication date
SG11202011311YA (en) 2020-12-30
WO2019222269A1 (en) 2019-11-21
CL2020002957A1 (es) 2021-04-16
AU2019271126A1 (en) 2020-12-10
PH12020551941A1 (en) 2021-08-16
EA202092727A1 (ru) 2021-04-20
CA3100333A1 (en) 2019-11-21
IL309891A (en) 2024-03-01
CO2020015380A2 (es) 2020-12-21
PE20211917A1 (es) 2021-09-28
IL278698A (es) 2021-01-31
BR112020023277A2 (pt) 2021-02-23
JP2021524439A (ja) 2021-09-13
US20210261592A1 (en) 2021-08-26
CN112513058A (zh) 2021-03-16
IL278698B1 (en) 2024-02-01
EP3794009A1 (en) 2021-03-24
US11827664B2 (en) 2023-11-28
KR20210021457A (ko) 2021-02-26

Similar Documents

Publication Publication Date Title
PH12020551941A1 (en) Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
EP4219713A3 (en) Products and compositions
MX2018004175A (es) Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2021014473A (es) Compuestos y metodos dirigidos a la tau humana.
BR112021025928A2 (pt) Métodos de preparação de ácido bempedoico e composições do mesmo
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
NZ757081A (en) Somatostatin modulators and uses thereof
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2022003907A (es) Compuestos y composiciones y usos de los mismos.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2023003230A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
MX2022000712A (es) Moduladores de nlrp3.
EA202090555A1 (ru) Фармацевтические композиции, содержащие антитела к бета-амилоиду
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
EP3395804A4 (en) NOVEL SPIROCHINONE DERIVATIVE COMPOUND, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE AGENT FOR PREVENTING OR TREATING NEUROLOGICAL ILLNESSES
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX2018013405A (es) Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular.
WO2021099966A3 (en) Novel benzothiophene derivatives and use thereof for stimulating mitochondrial turnover